How does the expression of Pregnane X receptor (PXR) change during the progression of Alzheimer's disease?
Best insight from top research papers
The expression of PXR is not specifically mentioned in the abstracts provided in the context of Alzheimer's disease. Therefore, there is no information available on how the expression of PXR changes during the progression of Alzheimer's disease.
Answers from top 5 papers
More filters
Papers (5) | Insight |
---|---|
The provided paper does not mention anything about the expression of Pregnane X receptor (PXR) during the progression of Alzheimer's disease. | |
The provided paper does not mention anything about the expression of Pregnane X receptor (PXR) during the progression of Alzheimer's disease. | |
107 Citations | The provided paper does not mention anything about the expression of Pregnane X receptor (PXR) during the progression of Alzheimer's disease. |
6 Citations | The provided paper does not mention anything about the expression of Pregnane X receptor (PXR) during the progression of Alzheimer's disease. |
1 Citations | The provided paper does not mention anything about the expression of Pregnane X receptor (PXR) during the progression of Alzheimer's disease. |
Related Questions
What does expression of IP3R reveals in PIP metabolism in alzheimer's?4 answersThe expression of inositol 1,4,5-trisphosphate receptors (IP3Rs) in Alzheimer's disease (AD) sheds light on phosphoinositide (PIP) metabolism. IP3Rs play a crucial role in regulating intracellular calcium levels, which are implicated in neurodegenerative diseases like AD. Mutant presenilins (PS) associated with familial AD enhance IP3R activity independently of amyloid beta production, leading to increased intracellular calcium signaling. Dysregulation of IP3R1-mediated calcium signaling is linked to the pathogenesis of AD, where excessive IP3R1 activity contributes to cytosolic calcium overload. Moreover, malfunction of the IP3R complex can lead to exaggerated calcium signals, potentially causing neuronal damage and cell death in AD. Therefore, the expression and function of IP3Rs in AD highlight their significant impact on PIP metabolism and calcium signaling dysregulation in the disease.
How is the TRPV1 Channel linked to Alzheimer's Disease progression?5 answersThe TRPV1 channel plays a crucial role in Alzheimer's Disease (AD) progression through various mechanisms. TRPV1 deficiency in AD models leads to neuroprotective effects by activating the BDNF/CREB pathway, preventing hippocampal apoptosis. Additionally, TRPV1 activation rescues Aβ-tolerant microglial dysfunction, restores immune responses, and reduces amyloid pathology and memory deficits in AD mice models. TRPV1 activation induces autophagy, regulates metabolism, and decreases amyloid and tau pathology, reversing memory deficits in AD mice. Moreover, TRPV1 modulation of lipid metabolism alleviates ApoE4-induced immune dysfunction, rescues memory impairment, and improves neuronal autophagy in AD models. Furthermore, PcActx peptide, a TRPV1 modulator, inhibits amyloid-related proteins, prevents calcium response, and activates the Akt/Gsk3β-mediated Nrf2 pathway, showing promise as a therapeutic agent for AD.
Can modulating P-GP transporter activity be an effective strategy for the treatment of Alzheimer's disease?5 answersModulating P-GP transporter activity shows promise as a potential therapeutic strategy for Alzheimer's disease (AD). Research indicates that P-GP plays a crucial role in clearing amyloid-beta (Aβ) peptides from the brain, with decreased P-GP levels contributing to Aβ accumulation in AD. Studies suggest that enhancing P-GP function can facilitate the export of Aβ across the blood-brain barrier and reduce Aβ brain levels, offering a novel approach for AD treatment. Additionally, inhibiting P-GP activity leads to impaired Aβ secretion, highlighting the importance of P-GP in Aβ clearance. Therefore, targeting P-GP to restore or augment its expression and function may hold therapeutic potential in mitigating Aβ pathology and potentially slowing down the progression of AD.
Is there any cancer cell line that express PXR (NR1I2) ?4 answersPregnane X receptor (PXR), encoded by NR1I2, is expressed in cancer cell lines. PXR expression has been observed in colon cancer stem cells (CSCs), head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). In addition, PXR has been found to be expressed in LS180 cells derived from the intestine. These findings suggest that PXR is present in various cancer cell lines and may play a role in cancer progression and drug metabolism.
How does TREM2 overexpression affect the progression of Alzheimer's disease?5 answersTREM2 overexpression has been shown to improve cognitive impairment in mice with long-term high-fat diet (HFD) feeding, without affecting body weight and glucose homeostasis. It upregulates synaptic proteins and rescues dendritic complexity and spine density, indicating an improvement in synaptic transmission. Additionally, TREM2 overexpression promotes microglial polarization towards the M2 anti-inflammatory phenotype, suppressing neuroinflammation and microglial activation. These findings suggest that TREM2 may be a novel target for intervention in obesity/diabetes-associated cognitive decline. However, the specific effects of TREM2 overexpression on the progression of Alzheimer's disease (AD) are not mentioned in the abstracts provided. Further research is needed to determine the impact of TREM2 overexpression on AD progression.
What are the micro RNA that effect the protein in Alzheimer diseases?3 answersMicroRNAs play a crucial role in Alzheimer's disease (AD) by regulating gene expression. Several microRNAs have been identified to affect the proteins involved in AD. MicroRNA-125b has been found to be downregulated in AD and its downregulation is associated with the neurotoxic effect of Aβ treatment in cortical neurons. Additionally, miRNAs are involved in the regulation of amyloid precursor protein (APP) metabolism, which is responsible for the production of amyloid-β (Aβ) in AD. The dysregulation of miRNAs in AD can serve as specific biomarkers for diagnosis and may represent new targets for pharmaceutical development. Overall, microRNAs have been shown to have a significant impact on the protein regulation in Alzheimer's disease.